$7.38
0.34% yesterday
Nasdaq, Nov 28, 07:21 pm CET
ISIN
US74365U1079
Symbol
TARA

Protara Therapeutics Inc Stock price

$7.41
+2.29 44.63% 1M
+4.28 136.58% 6M
+2.13 40.25% YTD
+4.47 151.87% 1Y
+4.02 118.76% 3Y
-17.02 69.68% 5Y
-572.20 98.72% 10Y
-393.80 98.15% 20Y
Nasdaq, Closing price Wed, Nov 26 2025
-0.16 2.05%
ISIN
US74365U1079
Symbol
TARA
Industry

Key metrics

Basic
Market capitalization
$285.7m
Enterprise Value
$153.1m
Net debt
positive
Cash
$132.7m
Shares outstanding
38.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
2.2
Financial Health
Equity Ratio
92.1%
Return on Equity
-26.9%
ROCE
-44.4%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-60.2m | -
EBIT
$-59.8m | $-66.9m
Net Income
$-52.9m | $-54.2m
Free Cash Flow
$-48.3m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-33.9% | -
EBIT
-29.8% | -36.5%
Net Income
-26.8% | -20.5%
Free Cash Flow
-35.1%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.3
FCF per Share
$-1.3
Short interest
7.4%
Employees
31
Rev per Employee
$0.0
Show more

Is Protara Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

Protara Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Protara Therapeutics Inc forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Protara Therapeutics Inc forecast:

Buy
92%
Hold
8%

Financial data from Protara Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 21 21
20% 20%
-
- Research and Development Expense 39 39
36% 36%
-
-60 -60
34% 34%
-
- Depreciation and Amortization -0.40 -0.40
136% 136%
-
EBIT (Operating Income) EBIT -60 -60
30% 30%
-
Net Profit -53 -53
27% 27%
-

In millions USD.

Don't miss a Thing! We will send you all news about Protara Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Protara Therapeutics Inc Stock News

Neutral
Seeking Alpha
9 days ago
Protara Therapeutics, Inc. ( TARA ) Discusses Interim Results From Phase II STARBORN-1 Trial of TARA-002 in Pediatric Lymphatic Malformations November 19, 2025 8:30 AM EST Company Participants Justine O'Malley - Senior Vice President of Investor Relations & Corporate Affairs Jesse Shefferman - Co-founder, CEO, President & Director Jacqueline Zummo - Co-Founder & Chief Scientific Operations Offi...
Neutral
GlobeNewsWire
9 days ago
80% of patients that completed treatment and 100% of patients that completed the eight-week response assessment achieved clinical success Clinical success achieved with one or two doses of TARA-002 in 88% of patients TARA-002 demonstrated favorable safety and tolerability profile with no serious adverse events reported Company to host conference call and webcast featuring Key Opinion Leader Dr....
Neutral
GlobeNewsWire
10 days ago
NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 19, 2025, to review new data from an interim analysis of the ongoing Phase 2 open-label STARBORN-1 ...
More Protara Therapeutics Inc News

Company Profile

Protara Therapeutics, Inc., a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is based in New York, New York.

Head office United States
CEO Jesse Shefferman
Employees 31
Founded 2006
Website protaratx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today